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Tumour necrosis factor (TNF) is produced by primary human macrophages in response to stimulation by
exogenous pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated mo-
lecular patterns (DAMPs) via Toll-like receptor (TLR) signalling. However, uncontrolled TNF production
can be deleterious and hence it is tightly controlled at multiple stages. We have previously shown that
Bruton's tyrosine kinase (Btk) regulates TLR4-induced TNF production via p38 MAP Kinase by stabilising
TNF messenger RNA. Using both gene over-expression and siRNA-mediated knockdown we have
examined the role of Btk in TLR7/8 mediated TNF production. Our data shows that Btk acts in the TLR7/8
pathway and mediates Ser-536 phosphorylation of p65 RelA and subsequent nuclear entry in primary
human macrophages. These data show an important role for Btk in TLR7/8 mediated TNF production and
reveal distinct differences for Btk in TLR4 versus TLR7/8 signalling.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
TNF production is precisely regulated at both the gene and
protein expression level [1]. Toll-like receptors (TLRs), by recog-
nising ligands as diverse as bacterial cell wall components and
nucleic acids, are important inducers of TNF production in disease.
In addition, recognition of endogenously derived damage-
associated molecular patterns (DAMPs) makes them key players
in the induction and maintenance of autoimmune inﬂammation
[2].
Non-receptor tyrosine kinases play a major role in TLR signalling
[3e5], and in particular, Bruton's Tyrosine Kinase (Btk), a member
of the Tec family of non-receptor protein tyrosine kinases (PTKs), is
a crucial regulator of TLR induced TNF production [6,7]. In humans,
a lack of functional Btk leads to X-linked agammaglobulinemia
(XLA), a condition characterised by both B cell deﬁciency and
ineffective immune responses to bacterial and viral challenge [8].
XLA patient monocytes show reduced production of TNF and IL-1b(N.J. Horwood).
, Imperial College London, Du
r Inc. This is an open access articlin response to TLR2 and TLR4 ligands [9,10] and stimulation of XLA-
derived dendritic cells with siRNA results in signiﬁcantly decreased
production of both TNF and IL-6 [11]. Btk deﬁciency in B cells re-
duces TLR9-induced production of IL-10, leading to elevated levels
of TNF, IL-6 and IL-12p40 [12,13] a ﬁnding that may explain the
increased levels of cytokines present in XLA serum [14].
In HEK293 cells Btk physically interacts with the cytoplasmic
Toll/IL-1 receptor (TIR) domains of TLRs 4, 6, 8 and 9 as well as the
adaptor molecules Myd88 and Myd88-adapter-like (Mal) [15].
Following stimulation, TLR receptors (except TLR3) recruit Myd88
via its cytoplasmic Toll/IL-1 receptor (TIR) domain. Various other
molecules including IL-1 receptor-associated kinases 1 and 4
(IRAKs 1 and 4), TNF receptor associated factor (TRAF) 6, TAB2/3
and TAK1 then associate with the receptor complex. IkB is phos-
phorylated by the TAK1-activated IkB kinase (IKK) complex, ubiq-
uitinated and degraded by the 26S proteasome. Following NFkB
release from the inhibitory IkB complex, p65RelA is phosphorylated
on a number of serines to regulate p65RelA nuclear translocation
and gene transactivation [16]. NFkB is considered to be essential for
TNF transcription, and over-expression of IkBa decreases TNF pro-
duction from LPS-stimulated human primary macrophages [17].
Here we provide evidence for Btk in TLR7/8 signalling in human
primary macrophages. Btk regulates TLR7/8-induced TNF produc-
tion at early time points via the 3'enhancer region of the TNF gene.
Moreover, we show that Btk controls the initiation of TNFe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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scription in response to LPS was less affected, revealing a previously
unreported distinction between TLR4 and TLR7/8-mediated TNF
gene transcription.
2. Materials and methods
Reagents and Antibodies. R848 and LPS were from Alexis Bio-
chemicals and macrophage colony-stimulating factor (M-CSF) was
from Peprotech. Polyclonal rabbit anti-Btk antibody for immuno-
precipitation was a gift from M. Tomlinson (University of Bir-
mingham, U.K.), mouse anti-Btk antibody (clone 10D11) for
Western blotting was from BD Bioscience and anti-GAPDH
(ab9484) and rabbit isotope control antibodies were from Abcam.
The phosphotyrosine clone 4G10 was fromMillipore. Cell Signaling
provided anti-IkBa (#9242), anti-phospho-p65RelA (Ser536) (for
Western blot; #3036), and anti-p65RelA (for confocal; #3033).
Anti-p65RelA (sc-372) for Western blotting was from Santa Cruz
Biotechnology.
Monocyte isolation and adenoviral infection. Following ﬁcoll-
hypaque centrifugation, monocytes were elutriated from PBMC as
previously described [17]. Monocytes were treated with M-CSF
(100 ng/ml) for 3e4 days prior to counting and re-seeding. Creation
of adenoviral constructs and method of infection as previously
described [17]. For double infections, cells were ﬁrst infected with
the luciferase adenovirus at multiplicity of infection (moi) 50:1 for
2h, rested for 4h in serum containing medium prior to secondary
infection at moi 100. Luciferase reporter assays were performed as
previously described [9,18].
Gene knockdown by siRNA. 5 106 primary human monocytes
were transfected with targeting siRNA or control oligunucleotides
(siControl D-001206-13 and human Btk SMARTpool M-003107-01,
Dharmacon, IL) at concentrations ranging from 100 to 300 nM us-
ing Human Monocyte Nucleofector Kit (Amaxa Biosystems, Ger-
many) according to manufacturer's instructions. After 24 h,
monocytes were cultured in 5% HIFCS phenol red free RPMI with
100 ng/ml M-CSF for a further 72h. STAT1 phosphorylation by
Western blot following siRNA nucleofection was assessed after a
further 24h in the absence ofM-CSF and stimulation± IFN (1 ng/ml)
for 5min.
Immunoprecipitation and Western Blotting. M-CSF-differentiated
macrophageswere plated on 10 cm2 petri dishes and serum starved
for 2h prior to stimulation. Cells were lysed in ice-cold lysis buffer
(20mM Tris-Base pH 7.6125mM NaCl, and 1% Nonidet P-40), con-
taining freshly added 10mM DTT, 100 mM Na2VO3, 5mM NaF, 1x
Protein Inhibitor Cocktail (Sigma). Debris was removed by centri-
fugation, and supernatants were pre-cleared with protein G-
sepharose. Btk was precipitated with polyclonal rabbit anti-Btk
anti-sera and protein G-sepharose for 1.5 h. Immunoprecipitated
complexes werewashed in lysis buffer before resolving on 10% SDS-
PAGE gel and transferring to nitrocellulose membrane (Millipore).
Themembranewas blocked for 1h in TBS-Tween (0.1%) with 2% BSA
for the detection of phosphorylated proteins or in 5% skimmedmilk
for other proteins.
Immunocytochemistry. After siRNA transfection, monocytes were
differentiated in M-CSF for 72h. Macrophages were plated on glass
coverslips (ECN 631-1578, VWR) and stimulated with R848 (1 mg/
ml). Cells were ﬁxed with 4% (w/v) paraformaldehyde in PBS for
15min at 37 C, quenched with 50mM NH4Cl/PBS for 10min, and
permeabilised with 0.1% (w/v) Triton X-100 in PBS for 5min.
Samples were blocked with 3% (w/v) BSA in PBS for 30min at room
temperature followed by incubation with anti-phospho-p65RelA
(Ser536) diluted in 3% (w/v) BSA in PBS for 1 h at room tempera-
ture. After washing, secondary antibody was added; phosphory-
lated p65RelA (Ser536) with Alexa Fluor 488 (A11034, Invitrogen),actin cytoskeleton with Alexa Fluor 546 Phalloidin (A22283, Invi-
trogen) and the nucleus with DAPI (D1306, Invitrogen). Samples
were mounted with ProGold antifade mounting media (P36934,
Invitrogen). Confocal ‘z’ stack were used to quantify the intensity of
staining by measuring the respective brightness of the pixels for
each of detection channels using Fiji image analysis software.
Cytokine measurements by ELISA. TNF concentration in super-
natants was determined by ELISA (BD Biosciences), according to the
manufacturer's instructions. Absorbance was read and analysed at
450 nm using a Fluostar Omega (BMG Labtech, Aylesbury, UK) plate
reader and analysed using MARS data analysis software.
Real-time RT-PCR. RNA was extracted from macrophages using
Blood RNA extraction kit (QIAGEN), and genomic DNA removed
using TURBO DNA-free kit (Applied Biosystems). cDNA was sub-
jected to real-time PCR analysis using SYBR Premix Ex Taq (Lonza)
on a Corbett Rotor-Gene 6000 (Qiagen). Primers for measuring
primary human TNF transcripts were 50-GCAGTCA-
GATCATCTTCTCG-30 and 50-GGTACAGGCCCTCTGATGGCAC-3’.
Mature human TNF transcripts were 50-CCTGCTGCACTTTGGAGT-
GATCGG-3’ & 50-GTACAGGCCCTCTGATGGCACCACC-30, respectively.
Primers for actin-related protein transcripts (ARP) were 50-
CGACCTGGAAGTCCAACTAC-30 and 50- ATCTGCTGCATCTGCTTG-3’.
Relative quantiﬁcation of gene expression was expressed as fold
mRNA/ARP as determined using the comparative DDCT method.
Statistical analysis. Values correspond to mean± SEM or SD. In
experiments with multiple groups, differences were ﬁrst evaluated
using repeated-measures ANOVA and then Dunnett's test to
compare group means. Unpaired Student's t-test was used when
comparing differences between two groups.
3. Results
3.1. TNF production following TLR7/8 stimulation requires Btk
Enzymatic activation of Btk is marked by tyrosine phosphory-
lation. Primary human macrophages were stimulated with either
LPS (10 ng/ml) or R848 (1 mg/ml) for 5, 10, 15 or 20min and tyrosine
phosphorylation of Btk determined by Western blot analysis. As
previously observed [9] an increase in Btk phosphorylation
occurred in response to LPS (TLR4) stimulation with a maximal
response at 10min (Fig. 1A). Likewise, an increase in Btk phos-
phorylation occurred within 10mins of R848 (TLR7/8) stimulation
(Fig. 1B).
To determine whether Btk modulates TLR7/8 driven TNF, Btk
was over-expressed as previously described [9] as conﬁrmed by
western blot (Fig. 1C). Cells were then stimulated with either LPS or
R848 and TNF production after 18 h was measured. Over-
expression of Btk resulted in signiﬁcantly increased TNF produc-
tion in response to both LPS and R848 (Fig. 1D and E). To test the
effect of Btk down-regulation on TNF production two siRNA du-
plexes; siBtk#9 and siBtk#11 were tested and produced similar
decreases in Btk expression (Fig. 1 F). In the absence of TLR stimuli
(NS), siRNA nucleofection alone did not induce any detectable
cytokine production (Fig. 1G and H). In the presence of R848,
siBtk#9 showed the greatest effect on cytokine production and
hence was used for the remaining experiments (Fig. 1G and H).
Three doses of siRNA were tested (100, 200 and 300 nM) and
200 nM was chosen as the concentration for subsequent experi-
ments. Additionally, there was no basal increase in STAT1 phos-
phorylation following RNAi knockdown indicating that subsequent
ﬁndings are attributable to Btk knockdown as opposed to the in-
duction of an interferon response (Fig. 1J). Following Btk inhibition,
TNF release was signiﬁcantly reduced from 4 to 10h after LPS
stimulation and 2e18h after R848 stimulation (Fig. 1K and L).
Interestingly the effect of Btk ablation was more pronounced and
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Fig. 2. Btk regulates TLR7/8-induced TNF transcription. (A) Schematic representation of the TNF gene indicating primer pair positions used for transcriptional start site (TSS) and
downstream regions of the gene. Monocytes were transfected with 200 nM Btk siRNA (siBtk) or control siRNA (siCon), M-CSF-treated for 4 days, and then stimulated with either LPS
(10 ng/ml) (B and D) or R848 (1 mg/ml) (C and E) up to 10h. TNF mature (B, C) and primary (D, E) mRNA levels measured by RT-PCR using primers for downstream or TSS regions of
the TNF gene. Graphs show mean values ± SD of triplicate measurements for a single donor: representative of 3 independent experiments using different donors.
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3.2. Effect of Btk depletion on TLR4-and TLR7/8-mediated TNF
transcription
TNF is controlled at a number of different stages in its produc-
tion. Our previous work showed that message stability is an
important control point for TNF production [9]. TNF is alsoFig. 1. Btk is required for cytokine production in TLR4 and TLR7/8 signalling. M-CSF-differentiate
or 1 mg/ml R848 up to 20 min. Btk was immunoprecipitated using anti-Btk antibody follo
Macrophages infected with adenovirus at moi 10 to 150 were left for 48 h. Btk expression in
infection, cells were stimulated with either LPS (10 ng/ml) or R848 (1 mg/ml) for 18h and TN
bar; empty adenovirus) for each moi. (F) Monocytes transfected with Btk siRNA (siBtk#9
expression assessed by Western blot. (G, H) TNF or IL-6 in supernatants was measured by EL
Monocytes were transfected with Btk siRNA (siBtk) or control siRNA (siCon) at 100, 200 or 3
buffer alone. Cell lysate expression of Btk was assessed byWestern blot. (J) Monocytes were i
After 24 h of M-CSF treatment, media was replaced, and after a further 24 h cells were pla
phosphorylation status of STAT1 and levels of BTK by SDS-PAGE and western blotting. (K, L)
then stimulated with either LPS (10 ng/ml) or R848 (1 mg/ml) for 18h; TNF concentration wa
Results shown combined data from 3 to 6 separate donors. Statistical analysis: student's t-controlled at the transcriptional level and data from other workers
in HEK293s and immortalised monocyte lines have suggested that
this is how Btk mediates its effect on TLR7/8 induced TNF [19].
To establish whether this is also true of primary human cells we
examined mature TNF transcripts in macrophages following siBtk.
Real-Time PCR with a primer set spanning an exon-exon TNF
sequence (Fig. 2A) were used for the detection of mature mRNA
[18]. Fig. 2B and C shows that mature TNF mRNA production lastsd macrophages were (A, B) serum starved for 2h prior to stimulation with 10 ng/ml LPS
wed by western blotting with 4G10 antibody. Anti-rabbit IgG as isotope control. (C)
cell lysates by Western blot using GAPDH as a protein loading control. (D, E) Following
F production assessed by ELISA. Btk over-expression was normalised to control (black
and #11) or control siRNA (siCon) at 200 nM then M-CSF-treated for 4 days and Btk
ISA from siRNA manipulated cells after 18hr with either no stimulus or 1ug/ml R848. (I)
00 nM and then M-CSF-treated for 4 days. B- was no transfection; Bþ transfection with
ncubated with no oligo (nil), control oligo or BTK oligo at 200 nM prior to nucleofection.
ted and stimulated ± IFN (1 ng/ml) for 5 min. Cell lysates were used to determine the
Monocytes were transfected with 200 nM siBtk or siCon, M-CSF-treated for 4 days, and
s assessed by ELISA. Cytokine levels are expressed as means of triplicate repeats ± SEM.
test, ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 3. Btk regulates TLR7/8-induced TNF via both promoter NFkB sites and downstream
regions of the gene. (A) Adenoviral luciferase reporters based on the human TNF gene.
Positions of NFkB sites (2/z/2a, 3 and 4/4a/b) are shown. AAA denotes site of poly-A tail.
X indicates position of point mutations used to destroy NFkB site(s). (B) M-CSF-
differentiated macrophages were infected with luciferase reporter adenovirus at moi
50 followed by AdBtk or AdCon at moi 100. After 24h cells were stimulated with R848
(1 mg/ml) and lysed after 6h. Values are normalised to non-infected controls and
represent combined data from >3 separate donors (means ± SEM).
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8 h. In comparison, LPS stimulated cells show a more transient in-
duction of TNF message; this may explainwhy R848 stimulated cell
cultures consistently had higher TNF expression levels. Following
Btk knockdown LPS-stimulated cells showed approximately 15%
decrease at 2 h and no more than a 50% decrease in transcript level
at 4 h (Fig. 2B), whilst in R848-stimulated cells mature TNF tran-
scripts were decreased by at least 80% at all of the time points
(Fig. 2C).
In response to Btk knockdown, primary TNF transcripts (ana-
lysed using primers over an intron-exon boundary of TNF; Fig. 2A)
showed a similar pattern demonstrating that the reduction in
transcript level is due to deﬁcient transcription rather than RNA
processing (Fig. 2D and E). Taken together, these data reveal
fundamental differences between the way that Btk controls TNF
production downstream of TLR4 and TLR7/8 stimulation with
R848-induced TNF mRNA being more Btk dependent than that
induced by LPS.
3.3. NF-kB sites in TNF promoter and a 252bp region of TNF 30UTR
are required for Btk effects
Transcription of TNF is mediated by a number of transcription
factors including AP-1, Oct-1 and NF-kB [20]. 4 distinct NF-kB
binding regions have been described within the TNF locus; 3 sites
(kB1, kB2/z/2a, kB3) within the promoter region and a fourth cluster
(sites 4, 4a and 4b) in the 30UTR. Site 4 plays an essential role in LPS-
mediated TNF transcription in macrophages and DCs [18,21] and
our previous studies have highlighted the importance of a 252bp
region in the 30UTR of TNF for TLR4-induced transcription [18].
To investigate the NF-kB sites, and other regions in the TNF lo-
cus, controlling Btk-mediated TLR7/8-induced transcription we
used a series of adenoviral constructs containing the TNF promoter,
30UTR and other downstream regions, linked to a luciferase re-
porter (Fig. 3A). Over-expression of Btk produced a 2-fold increase
in TLR7/8 driven luciferase production in the 501251 construct
containing the full-length promoter (1187bp) and downstream
sequences (1251bp) (Fig. 3B). Luciferase production by the 501037
construct (lacking the terminal 214bp and NF-kB sites 4a and 4b)
and the ‘site4X’ construct (includes a mutation that inactivates NF-
kB site 4), also show a 2-fold increase in luciferase production
indicating that neither the terminal 214bp nor the site 4 NF-kB
cluster are required for Btk to inﬂuence TLR7/8-induced TNF
production.
In contrast, the 5'only construct, the 4X NF-kB construct (all NF-
kB sites destroyed by point mutations), and the 50785 construct,
which lacks a 252bp region in the 30UTR, were not able to increase
luciferase production after Btk over-expression (Fig. 3B). Thus
demonstrating the need for both the NF-kB sites in the TNF pro-
moter (site 1, cluster 2, site 3), and the 252bp region in the 30UTR to
mediate the effect of Btk on TLR7/8 driven TNF production.
3.4. Btk mediates phosphorylation and nuclear entry of p65RelA in
response to TLR7/8
Studies to determine the effect of Btk on TLR7/8 mediated IkBa
activity showed that knockdown of Btk had no effect TLR7/8-
mediated phosphorylation and degradation of IkBa (Fig. 4A).
However, NF-kB activity can be regulated at many levels. In
particular, p65RelA phosphorylation on Ser536 is described to be
independent of IkBa activity and to be necessary for p65RelA nu-
clear entry. After Btk knockdown, confocal microscopy experiments
showed a signiﬁcant reduction (***p ¼ 0.0003) in p65RelA trans-
location into the nucleus in human macrophages upon TLR7/8
stimulation (Fig. 4B and C).4. Discussion
Understanding how TNF expression is controlled is crucial for
the next generation of anti-inﬂammatory therapies [22]. TLR7 and
8 both recognise single stranded RNA, which is central to the
recognition of both viral and bacterial pathogens [23,24]. The
ability of TLR7/8 to recognise endogenously released RNA has im-
plications for autoimmune diseases where TLR7/8 contributes to
inﬂammation in RA and SLE [25,26].
Btk is a critical signalling component of a wide variety of im-
mune receptors, including Fc receptors, gp130 containing cytokine
receptors, and the B cell receptor where it is required for the acti-
vation of NF-kB [6,27]; the cumulative effect of Btk depletion is an
impaired immune response. Downstream of TLR7/8 engagement
numerous signalling pathways are activated, including the NF-kB,
MAPK, AP1 and the IRF family [23,28]. Doyle et al. showed that TLR8
stimulation activates Btk in THP1 cells via phosphorylation of
tyrosine 223 and increased autokinase activity [19]. TLR8-mediated
Ser536 phosphorylation of p65RelA in murine BMDM was signiﬁ-
cantly reduced in Xidmice [19]; our data agrees with these ﬁndings
and extends them to show that TLR7/8 mediated activation of Btk
Fig. 4. Btk down-regulation decreases R848-induced p65 phosphorylation. (A) Monocytes
were transfected with 200 nM Btk siRNA (siBtk) or control siRNA (siCon), M-CSF-
treated for 4 days, and then stimulated with R848 (1 mg/ml) for 90min. p65 RelA
phosphorylation and degradation of IkBa was assessed by western blotting with anti-
p-p65 (Ser536) and anti-IkBa antibodies. Blot represents one of 3 independent ex-
periments. (B) siRNA transfection of monocytes was performed as described in (A).
Primary human macrophages were plated on glass coverslips, stimulated with R848
(1 mg/ml) for 30min, ﬁxed and stained for phosphorylated p65RelA (green), actin (red)
and nucleus (blue) (scale bars¼ 10 mm). Images are representative of 3 independent
experiments. (C) Staining intensity of p-p65 in the nucleus. Mean values from 2 to 3
nuclei per each condition, for each of 3 independent experiments (means ± SEM).
Statistical analysis: student's t-test. ***p ¼ 0.0003. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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distinct differences in the requirement for Btk in TLR4 and TLR7/8
signalling within the same cell type. In TLR7/8 signalling Btk acts
upstream of NF-kB activation, regulating the serine phosphoryla-
tion of p65RelA and thereby its nuclear localisation - consequently,
TNF transcription is signiﬁcantly inhibited without Btk. In contrast,
despite similar reductions in p65RelA binding to NF-kB sites in Btk
depleted cells after LPS (TLR4) stimulation, transcription of TNFwas
largely un-affected. Btk-independent TNF transcription following
LPS suggests that additional transcription factors/regulatory
mechanisms may be active for TLR4 signalling that are absent for
TLR7/8.
Phosphorylation of p65RelA occurs after release from theinhibitory IkBa complex and the importance of Ser536 phosphor-
ylation of p65RelA is demonstrated by the mutation of Ser536 to
alanine which abolishes the interaction of p65RelA with the tran-
scriptional coactivators p300 and CREB-binding protein (CBP)
thereby decreasing transcriptional activation [29,30]. Btk lies up-
stream of this phosphorylation event in a number of systems,
including signalling via TLR4 and the B cell receptor [30,31], but the
mechanism is unknown. p65RelA can be phosphorylated on Ser536
by IKKa and IKKb for example, but neither molecule has been
described to interact with Btk.
Non-receptor tyrosine kinases are attractive targets for thera-
peutic intervention as small molecule inhibitors are readily syn-
thesised [32]. Btk inhibitors have demonstrated considerable
success in clinical trials, particularly in combating B cell malig-
nancies [33,34] and in the treatment of autoimmune disorders such
as lupus and inﬂammatory arthritis in animal models [35e37]. Btk
inhibition acts not only via reduced B cell development and func-
tion, but also on other cell types such macrophages limiting cyto-
kine and chemokine production [38,39].
We have used loss of function and overexpression manipulation
technologies to demonstrate the importance of Btk in response to
different TLR ligands in primary human macrophages. Btk plays an
important role in the TLR7/8 mediated induction of TNF and there
are clear differences between TLR4 and TLR7/8-mediated TNF
production. These data add important insight into the control of
TNF production in primary human cells and may suggest molecular
targets for the development of more efﬁcient anti-inﬂammatory
therapeutics.
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